Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress

Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share.

The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the offering to advance the clinical development of its product candidates. It also plans to invest in its manufacturing facilities and in working capital. A portion of the net proceeds could also be used to acquire, license, and invest in complementary products, technologies, and intellectual property.

The $175 million offering comes as the company continues to experience strong patient recruitment in the lead program, VMT-α-NET, for neuroendocrine tumors. The candidate drug remains well-tolerated and demonstrates durable disease control in clinical trials. Perspective Therapeutics will provide mid-year updates on the trials.

“We are making disciplined investments to continue to innovate both products and processes, which positions us to be a leading commercial radiopharmaceutical player. We expect to share maturing clinical data across all of our programs in 2026,” said Thijs Spoor, Perspective’s CEO.

On January 30, H.C. Wainwright raised its price target on Perspective Therapeutics to $12 from $10, keeping a Buy rating. The upgrade came after Sanofi dropped its competing SSTR2-targeted radioimmunotherapy agent, Alphamedix, leaving Perspective’s 212Pb‑VMT‑α‑NET as the only lead‑based option. Recent ASCO GU 2026 data showed strong results, with 76% of patients progression‑free and a 39% response rate in Cohort 2. Perspective is now testing higher doses in Cohort 3, which analysts expect could further improve outcomes.

Perspective Therapeutics, Inc. (NYSE:CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies (TATs) for cancer using the isotope Pb-212. Its theranostic approach combines imaging (Pb-203) with therapy (Pb-212) to deliver targeted radiation directly to tumors, minimizing damage to healthy tissue, with active trials for neuroendocrine tumors and melanoma.

While we acknowledge the potential of CATX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.